Snowden Capital Advisors’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History
Bought
Maintained
Sold
Other funds holding TEVA
Snowden Capital Advisors's TEVA Position: Q2 2026 in Review
Snowden Capital Advisors increased its Teva Pharmaceutical Industries Limited (TEVA) stake by 3.5% in Q2 2026, buying an estimated $71.4K and bringing the position to 63,441 shares worth $2.15M. The position accounts for 0.05% of the portfolio, ranked #345.
Snowden Capital Advisors first reported a position in TEVA in Q4 2021 and has held it in 14 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- Snowden Capital Advisors held 63,441 shares of Teva Pharmaceutical Industries Limited worth $2.15M as of Q2 2026.
- Snowden Capital Advisors bought 2,145 Teva Pharmaceutical Industries Limited shares in Q2 2026, an estimated $71.4K.
- Teva Pharmaceutical Industries Limited made up 0.05% of Snowden Capital Advisors's portfolio in Q2 2026, its #345 holding.
- Snowden Capital Advisors first reported a position in Teva Pharmaceutical Industries Limited in Q4 2021 and has held it in 14 quarters since.
- 676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.
Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.